Key result
Bempedoic acid effectively lowers LDL-C and hsCRP alone or paired with standard lipid-lowering therapies.
Why the study?
Despite the effectiveness of statins, residual cardiovascular risk remains and additional lipid-lowering drugs added to statin therapy have shown mainly modest or negative outcomes, creating a need for new effective oral agents in combination therapy for lipid disorders.
Answers are grounded in this paper and cite their sources.
INTRODUCTION: Despite the effectiveness of statins in the treatment of lipid disorders, residual risk still exists, and hitherto studies where additional drugs were added to statin therapy have been mainly negative or the outcomes were very modest. Therefore there is still a need for new and effective oral agents in the combination therapy of lipid disorders. Areas covered: The review covers the current state of knowledge on the mechanism of action of bempedoic acid (ETC-1002) and results from recent clinical studies. Expert opinion: ETC-1002 is a novel oral lipid-lowering therapy. The reduction of both low-density lipoprotein cholesterol (LDL-C) and high sensitivity C-reactive protein (hsCRP) demonstrated by ETC-1002 in clinical trials suggests that agent may have the potential for CV risk reduction. Adverse effects of current lipid-lowering agents can be dose-limiting, and combination approaches to lipid-lowering may often be utilized for optimal CV risk reduction. Because of this, new lipid-modulating drugs are urgently required. ETC-1002 has a unique mechanism of action (adenosine triphosphate-citrate lyase inhibition). It has been shown to be safe in combination with statins as well as ezetimibe, and appears to effectively lower LDL-C and has the potential to reduce the risk of muscle-related adverse events, which can limit the utilization and effectiveness of statin therapy.
No takes yet. Share an insight, caveat, or question.
Penson et al. (2017) conducted a review in Hyperlipidaemia. Bempedoic acid vs. Placebo or active comparators (ezetimibe, statins) was evaluated. Bempedoic acid effectively reduces LDL-C and hsCRP across various hypercholesterolaemic populations, demonstrating a favorable safety profile and additive lipid-lowering effects when combined with statins or ezetimibe.
Synapse has enriched 10 related papers. Consider them for comparative context: